Flagship Pioneering launched Expedition Medicines with a $50 million commitment to develop covalent‑binding small molecules using generative AI, quantum chemistry and chemoproteomics. The new company emerged from three years of incubation and announced an early collaboration with Pfizer on prostate cancer targets. Flagship’s move builds on a broader surge in AI‑first drug discovery startups and deepens the firm’s portfolio of platform companies aimed at transforming small‑molecule design. Expedition will focus on covalent binders—a modality that can address previously intractable targets—leveraging large‑scale experimental data to train generative models. The launch underscores continuing investor appetite for platform plays that integrate AI and automation; success will hinge on translating in‑silico predictions into validated leads and scalable chemistry. Industry watchers will monitor Expedition’s academic collaborations, validation data and any ensuing partnerships or financings.